Ignite Creation Date:
2025-12-24 @ 4:45 PM
Ignite Modification Date:
2026-01-01 @ 10:29 PM
Study NCT ID:
NCT05231850
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-02-09
First Post:
2022-02-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-07
First Submit QC Date:
None
Study First Post Date:
2022-02-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-07
Last Update Post Date:
2022-02-09
Last Update Post Date Type:
ACTUAL